Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02PVB
|
|||
| Former ID |
DNC002874
|
|||
| Drug Name |
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One
|
|||
| Synonyms |
Anthra[1,9-cd]pyrazol-6(2H)-one; 129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra-1,9-pyrazol-6-none; SP-600125; CI 70300; 2H-Dibenzo[cd,g]indazol-6-one; JNK Inhibitor II; SAPK Inhibitor II; NSC 75890; UNII-1TW30Y2766; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; EINECS 204-955-6; 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE; BRN 0746890; CHEMBL7064; MLS002693964; CHEBI:90695; ACPOUJIDANTYHO-UHFFFAOYSA-N; 1TW30Y2766
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H8N2O
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O
|
|||
| InChI |
1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)
|
|||
| InChIKey |
ACPOUJIDANTYHO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 129-56-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
117321, 3144734, 3308697, 3724860, 3967281, 4726008, 5604123, 7885383, 7980045, 8156016, 10318986, 11111809, 11114107, 11120216, 11120704, 11121192, 11121718, 11122198, 11147299, 11362820, 11365382, 11367944, 11370871, 11370872, 11373545, 11376106, 15172126, 17405036, 24278395, 26536949, 26752203, 26752204, 26758988, 26758995, 29227191, 46392887, 46507936, 46509480, 47440505, 47440506, 47515564, 47589208, 47662529, 47736732, 48110706, 48110707, 48185213, 49830715, 49870568, 50104867
|
|||
| ChEBI ID |
CHEBI:90695
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5273). | |||
| REF 3 | c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81. | |||
| REF 4 | Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.